Former Division Of Nonprescription Clinical Evaluation Head Leonard-Segal Talks About OTC Switches Past, Present And Future
This article was originally published in The Pink Sheet Daily
Andrea Leonard-Segal and Melissa Furness talked with “The Tan Sheet” about the evolving opportunities for Rx-to-OTC switch and the significance of recent switches. Leonard-Segal, the former director of FDA’s Division of Nonprescription Clinical Evaluation, and Furness, a former DNCE supervisory consumer safety officer, started a consultancy to offer guidance on OTC switch programs and other regulatory areas.
You may also be interested in...
Plan B One-Step OTC Proposal Leaves Plaintiffs, Judge Korman Wary
The Center for Reproductive Rights and other plaintiffs suing FDA say the agency’s plan to approve only Teva’s Plan B One-Step for universal OTC sales, but not less-expensive generic emergency contraceptives, would not provide sufficient access for all women.
FDA’s Broad Power Can Overcome NSURE Labeling Obstacles – Attorney
Attorney Richard Kingham says the agency has authority to require broadly defined labeling for Rx-to-OTC switches, as well as to obligate generics to follow the same measures as innovator products. Consultant George Quesnelle says FDA’s openness to novel switch strategies on a case-by-case basis is key.
Sponsors Should Hang Tight On “New Paradigm” Switch – CDER’s Leonard-Segal
The director of FDA’s Division of Nonprescription Clinical Evaluation advises firms to wait to submit Rx-to-OTC switch applications until the regulations are revised to allow for expanded conditions of safe nonprescription use.